News Articles for Argent BioPharma

This week's Bulls N' Bears Runner of the Week is … Sparc Technologies. The company is developing new-age hydrogen technology using sunlight to split water without the use of an electrolyser. Argent Biopharma raised funds at a significant premium to its last closing price while Australian Mines boosted its scandium resource and Dimerix revealed a tie-in with a Japanese pharmaceutical firm to treat kidney disease.

Our board moves wrap includes Dianne Angus, Geoff Pocock, Andrew Chapman, Tod McGrouther, Gaurav Gupta, Mark Licciardo, Joel Ives, Karen Logan, Joan Dabon, Harry Spindler, Dan Robinson, Stephen Parker, Ross Walker, Stephen Carter, Grant Lukey, Rhett Morson, Bruce Rathie, Alec PIsmiris, Geoff Stalley, Kenneth Hall, Cathy Moises, and Brady Hall.

Our board moves wrap includes Ramon Soares, Benjamin Donovan, Ziggy Lubieniecki, James Smith, Sandra Bell, Arron Canicais, Andrew Nesbitt, Asimwe Kabunga, and Lily Zhao.

ASX-listed medical and cosmetic cannabis company MGC Pharmaceuticals has sacked a senior manager after discovering they breached the company's trading policy.

Our board moves wrap includes Stephen Windle, Robert Black, Joanna Kiernan, Erlyn Dawson, Alessandra Gauvin, Brett Tucker, Layton Mills, Brett Mitchell, Nativ Segev, Stephen Parker, Duncan Anderson, Danielle Lee, Matt Adams, Caroline Brokvam, Ian Finch, Donna Gentile O'Donnell, and Lisa Gray.

Our board moves wrap includes Chris Radin, Sheila Khama, Stirling Ross, Gerry Kaczmarek, Tony Kiernan, Derek Humphry, Dale Richards, Nerida Schmidt, Patricia Farr, Simon Robertson, Susan Park, Peter Webse, ChongTao Xu, Andrew Taplin, Carol Marinkovich, Rowan Harland, Arron Canicais, David Lim, Andrew Woskett, Benjamin Donovan, and Shaun Menezes.

Our board moves wrap includes Krista Bates, Lee Goddard, Eric Streitberg, Kelly Moore, Michelle Kennedy, Catherine Anderson, Scott Mathewson, Alan Rule, Michael Fry, Susan Park, and Evan Hayes.

Our board moves wrap includes David Southam, Peter Oliver, Yifat Steuer, Brett Mitchell, Curtis Abbott, Clint McGhie, and Paul Dalgleish.

Our board moves wrap includes Martin Stein, Matthew Worner, Cameron O'Brien, Rebecca Moylan, Rachel Kerr, David Lenigas, Simon Andrew, Xavier Braud, and Simon Bolster.

Shares in MGC Pharmaceuticals have risen more than 40 per cent after the WA company revealed first orders for its plant-derived medicinal products in the US.

Our board moves wrap includes James Brown, Gregory Bittar, Adrian Byass, Steve Brockhurst, Nadine Barry, Blair Snowball, Harry Miller, Ashley Lim, Shirley In't Veld, Graeme Smith, Arshad Muhammad, Marcus Goh, Tome Jongue, YiCheng Chen, Eric Kong, Piers Lewis, Victor Goh, Daniel Tydde, and Robert Ierace.

Our board moves wrap includes Trevor Harris, Antony Beckmand, David Lim, Mel Ashton, Dean Hely, Wayne McGrath, Gary Davison, Peter Cook, and Wayne Bramwell.

Biopharma company MGC Pharmaceuticals has proposed to buy an Israeli clinical research business for $6 million in shares.

The strong growth of the medicinal cannabis industry will need to be supported by research for the sector to take the next step.

Today's board moves wrap includes Alexander Burns, Campbell Olsen, Narelle Warren, Rachel Kerr, Ian Cunningham, Nicholas Bolton, Neville Bassett, and Tudor Marsden-Huggins.

Our board moves wrap includes Michael Edwards, Chris Hansen, Evan Hayes, and Paula Raffo.

ASX-listed MGC Pharmaceuticals has teamed up with the University of Notre Dame in Perth to undertake a new clinical trial for its “CogniCann” phytocannabinoid-derived medicine, after the first bulk shipment of the medicine arrived in Australia. Management said CogniCann was developed with the specific aim to treat symptoms associated with dementia and Alzheimer's disease and it is already available under prescription in Australia.

Medicinal cannabis player MGC Pharmaceuticals has inked a seven-year supply deal with Brazilian medical cannabis company Onix, with an estimated value of at least $1.65 million in the first year. From year two, the deal, which will see Onix purchase a bulk order of MGC Pharma's pharmaceutical grade products, has an estimated value of at least $4.1 million per year.

ASX-listed MGC Pharma has secured a key market in Europe after signing an exclusive, commercial wholesale supply agreement with Polish NGO, Cannabis House Association and the University of Lodz to supply a large-scale research project in Poland. Under the deal, MGC Pharma will supply its medicinal cannabis-based, cannabinoid medicine products to up to 250 pharmacies and provide scientific support to the commercial research study whilst gathering participant data.

MGC Pharmaceuticals has established a distribution agreement to produce and supply its cannabis based medicines to Anden Bio Naturals, giving the ASX listed company access to South American networks containing over 7,500 pharmacies, private clinics and an oncological private insurance system that has over one million listed clients. MGC's pharmaceutical-grade phytocannabinoid products are emerging as an alternative to conventional drugs.

Medicinal cannabis company, MGC Pharmaceuticals, has inked a new supply agreement that will generate an immediate revenue stream from THC Global Group Limited who will white label MGC's pharmaceutical-grade phytocannabinoid, or “CBD” products to the Australian and New Zealand markets. The products will be sold under THC's “Canndeo” brand and are not expected to compete with MGC's existing cannabis-based product lines.

Medicinal cannabis player, MGC Pharmaceuticals, has unveiled a new medicinal cannabis-based line for Australian and New Zealand markets to be called “Mercury Pharma” with its first product, Mercury Pharma 100, a prescription-only 100mg/mL cannabidiol product. The company has received purchase orders for over 2,000 product units already, which will see revenues of around $270,000 realised.

ASX listed medical cannabis player, MGC Pharmaceuticals, will receive the first bulk shipment of its “CogniCann” product that will see the start of its phase IIb clinical trials to treat dementia and Alzheimer's patients kick off. CogniCann is a GMP certified, pharmaceutical grade, medicinal cannabis product specifically developed for the treatment of dementia symptoms to improve specific cognitive functions.

MGC Pharmaceuticals has expanded the number of patients prescribing for or being processed to receive prescriptions for its medical cannabis-based pharmaceutical products in Australia, the UK, Brazil and Ireland with the company racking up over 1800 prescriptions to-date. Management said the milestone readily demonstrates its strengthening position and momentum in those key markets, with its sales graph continuing to climb month by month.

MGC Pharmaceuticals has taken a major step towards capturing the growing Latin American medicinal cannabis market by joining forces with Brazil's leading merchant bank in a ground breaking sales and distribution deal. The joint venture will see MGC and BrasilInvest not only sell and distribute MGC's phytocannabinoid-derived medicines in Brazil, but also in neighbouring countries where the use of medical marijuana has been approved.

MGC Pharmaceuticals has received a Government grant to support its research and development work relating to phyto-cannabinoid derived medicines to treat the symptoms of dementia and Alzheimer's. According to the Australian Bureau of Statistics, dementia is the second leading cause of death for Australians, which means that MGC will have a sizeable addressable market if it's cannabis-based medicinal products can have an impact on this debilitating disease.

MGC Pharmaceuticals has expanded the number of patients prescribing for or being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in Australia and the UK to around 500 with the company racking up its 1000th prescription this month. Management said that the key milestone readily demonstrates its strengthening position and momentum in those key markets, with its sales graph continuing to climb month by month.

MGC Pharmaceuticals has expanded the number of patients prescribing for or being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in both Australia and the UK to beyond 600. The company said that the key milestone readily demonstrates its strengthening position and momentum in those markets to meet the demand for its proprietary standardised, affordable cannabis-based medicines.

MGC Pharmaceuticals has expanded the number of patients now prescribing for or being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in Australia and the UK to beyond 200. The company said that the key milestone readily demonstrates its strengthening position in those markets to meet the demand for its proprietary standardised, affordable medicines on a global scale.

A summary of last week's smaller deals that did not get included in our daily news coverage.

MGC Pharmaceuticals has received Human Research Ethics Committee approval to carry out a clinical study comparing the effectiveness of its medical cannabis products for the treatment of severe epilepsy. This will compare its pharmaceutical-grade low tetrahydrocannabinol medicine authorised for prescription as an Investigational Medicinal Product in Australia and the UK, against its 100% cannabidiol product.

ASX-listed MGC Pharmaceuticals has partnered with the Slovenian Institute of Hop Research and Brewing, or “IHPS”, to carry out a ground-breaking, large-scale research project on the use of cannabis for medicinal purposes. The research will focus on the cultivation of cannabis for medical purposes and the standardisation of the process for isolating and extracting an active pharmaceutical ingredient for medicinal use.

MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance. The trial seeks to overturn legislation that forbids medical cannabis users from driving and will also provide safety data required for the European Medicines Agency and Australian Therapeutic Goods Administration product registration.

Medicinal marijuana player, MGC Pharmaceuticals, is looking to tap into one of Europe's largest public markets through a dual listing on the London Stock Exchange in the second half of the 2019 calendar year. The company will be one of the first medical cannabis companies to list in the UK since legislation was changed in 2018 to allow doctors to prescribe medical cannabis to patients.

MGC Pharmaceuticals has added another notch to its belt with 100 patients that have been prescribed or are being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in Australia. The company has also extended its local reach after Tetra Health, who assists medical professionals and patients to obtain safe access to medicinal cannabis products, added MGC's products to their product range.

MGC Pharmaceuticals has received the green light to start construction of its large scale, GMP compliant medical cannabis production facility in Malta that will increase its existing production capacity after signing a long-term lease agreement for the 6,000 square metre site. The site works for the facility will commence immediately and the company plans to start construction of the multi-storey building during the current quarter.

MGC Pharmaceuticals and Chinese e-commerce marketplace YuShop Global have kicked off a full marketing and sales campaign for MGC's cannabis-based nutraceuticals following a successful eight-week test campaign. Under the distribution agreement between the two companies, YuShop will sell MGC's nutraceutical products to consumers via its online platform and network of retail channel partners, which include 1,500 luxury spas.

MGC Pharmaceuticals' cannabinoid formulations have demonstrated effectiveness in fighting brain cancers in ground-breaking pre-clinical trials conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana in Slovenia. The formulations inhibited the viability of cancerous glioblastoma cells taken directly from a patient and caused a significant fraction of the cancer's stem cells to die.

MGC Pharmaceuticals' seed-to-pharmacy strategy is picking up significant momentum with the ASX-listed company reporting revenues of $763,000 in the fourth quarter ended 30 June 2019. The result is due in part to the receipt of $469,000 in revenue from private Canadian cannabis investment company CannaGlobal for cannabis-based cosmetic raw materials under their five-year supply agreement.

ASX-listed MGC Pharmaceuticals continues to spread its wings, signing an agreement with Germany's Mexacare for the distribution of the company's medical cannabis products to Germany, Austria and Switzerland. Germany's medical cannabis market alone was worth €133 million in 2018 and is estimated to grow to €7.7 billion by 2028, making it a key emerging market for MGC.